India is witnessing a concerning surge in COVID-19 cases with active cases jumping over 5,364 as of June 7, as per the COVID dashboard, Ministry of Health and Family Welfare. The figure marks a sharp increase from only 257 active cases on May 22. More importantly, more than 50% of the new infections are in the 25-to-50-year age group the working population which has caused alarm among public health officials.

The number of new COVID-19 infections reported on a daily basis continues to slowly rise. On June 6, 564 cases were added in India, increasing the active caseload to 5,364. The number has now crossed 5,364, indicating an upward trend. Along with the increasing infections, at least seven fatalities were recorded within a 24-hour period, with the departed including those from West Bengal (4), Maharashtra (3), Delhi (2), Kerela (2) and Karnataka (3). All six of the seven deaths were older patients with comorbidities like diabetes, hypertension, or pneumonia. The youngest death was in a five-month-old male infant with pre-existing respiratory problems.

Also Read: Can Right To Die Be Practiced By Non-Terminally Ill Patients?

These new cases are caused, according to experts, by newly emerging subvariants such as LF.7, XFG, JN.1, and more recently identified NB.1.8.1. These variants are said to be more transmissible and have partial immune escape characteristics but, as of yet, have not shown increased disease severity.

Experts are seeing a trend towards mild to moderate symptoms, but the rate of infection is worrying as it is impacting the productive segment of the population and may stretch the healthcare machinery if not contained.

COVID-19 Cases: Kerala, Delhi, and Maharashtra Among Worst-Hit States

Kerala is still the hotbed of this new wave, with more than 1,487 active cases according to the latest report. Delhi (562), West Bengal (538), Maharashtra (526), and Gujarat (508) take second place. The Gujarat state has registered a high count of infections in the age group of 25-50 years, which has contributed to more than 50% of its 700+ total cases.

Also Read: First Sign Of Diabetes Might Show Up In Your Eyes—Here’s What To Look For

Surprisingly, officials also noted that around 10% of new cases in Gujarat were infants under the age of one. The elderly population, which bore the brunt of earlier waves, has seen relatively fewer infections in the current resurgence. This shift in demographic impact is being closely monitored by epidemiologists.

New COVID Symptoms To Note

In contrast to the previous waves where dramatic cases of anosmia (loss of smell) and ageusia (loss of taste) were observed, present patients are reporting a different constellation of symptoms. The most frequently reported symptoms are high-grade fever, intense muscle aches (myalgia), and gastrointestinal symptoms such as diarrhea.

This wave clinically is presenting differently. Patients, particularly those in younger age groups, are presenting with intense body pains and fever instead of respiratory complaints.

Covid-19: Hospitalization Rates and Deaths

Whilst the figure of cases is rising, hospitalization rates continue to be fairly low — ranging at about 5%. Nevertheless, the seven recent deaths serve as a stark reminder of the risk posed to vulnerable groups. Ministry data show all victims had comorbidities such as seizures, respiratory failure, kidney disease, and cancer.

Three of the recent Gujarat fatalities included young women aged 18, 20, and 47, all from Ahmedabad. "This is not common and highlights the need to not ignore any symptoms," said a senior health official.

Also Read: 2 Infants Died Of Whooping Cough In Kentucky, Health Officials Report; Who Should Get A Booster Shot?

The Indian government has sent advisories to every state and union territory in order to be prepared. This involves keeping proper stocks of oxygen, antiviral drugs, and ICU beds. States have also been instructed to distinguish between COVID-19 and other viral fevers, which have common symptoms.

A ministry senior official observed, "We are calling for all states to be on their toes and to intensify surveillance, particularly in urban areas and public transport hubs."

Hospitals and clinics in major metros are keeping a lookout, with training and testing protocols of the staff being revised to account for the evolving clinical presentation of the disease.

Covid-19: Vigilance Needed Even With Vaccination Efforts

India has come a long way in COVID-19 vaccination with more than 2.2 billion doses given so far, but the new variants have again pushed to the forefront the question of booster doses, particularly among frontline workers and the elderly.

Vaccination is not a static shield. As the virus mutates, so should our immunity. It's important to remain current with booster doses if they are suggested.

Although hospitalization and serious cases are still low, the recent spurt in COVID-19 cases in India is a stark reminder of how unpredictable the virus has been. With variants spreading and attacking younger people, a joint effort through vigilance, prompt testing, booster vaccinations, and responsible public action is a must.

For the time being, health authorities keep a close watch on trends, advising people not to ignore mild symptoms and to follow basic precautions such as hand hygiene, wearing a mask in crowded places, and seeking a test when symptomatic.

The US Food and Drug Administration (FDA) has granted approval to Inlexzo (gemcitabine intravesical system) for the treatment of certain types of bladder cancer. This decision marks a milestone for patients with Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle-invasive bladder cancer (NMIBC), particularly those living with carcinoma in situ (CIS), with or without papillary tumors.

Unlike systemic therapies, Inlexzo works through a novel drug-releasing intravesical system designed for extended local delivery of gemcitabine into the bladder. For patients who wish to preserve their bladder and avoid radical surgery, the approval opens a long-awaited alternative.

Bladder cancer is the sixth most common cancer in the United States, disproportionately affecting older adults. Patients with NMIBC often start with BCG immunotherapy, the gold standard treatment. While many respond well initially, a significant proportion develop resistance or fail to sustain remission.

For these patients, the only widely recommended option has been radical cystectomy—a surgery to remove the bladder. Though effective, the procedure carries high risks, including a 3–8 percent post-surgical mortality rate, long recovery periods, and significant impact on quality of life. Many older patients are either unfit or unwilling to undergo the operation.

What this really means is that patients who have exhausted BCG therapy have been left with limited, often life-altering choices. Inlexzo offers a chance to delay or avoid bladder removal while still pursuing effective treatment.

The FDA’s approval was based on results from the SunRISe-1 phase 2b trial, a single-arm, open-label study. Findings showed:

• 82 percent of patients achieved a complete response following treatment.
• 51 percent of those maintained their response for at least a year.

Dr. Sia Daneshmand, principal investigator of SunRISe-1 and a urologic oncologist at the University of Southern California, emphasized the significance of these results, “I see many patients that ultimately become BCG-unresponsive and often face life-altering bladder removal. In my experience, Inlexzo is well tolerated and delivers clinically meaningful results. This will change the way we treat appropriate patients that haven’t responded to traditional therapy.”

Such durability of response signals a meaningful step forward in NMIBC care, particularly for patients for whom cystectomy is not feasible.

What Is Non-Muscle-Invasive Bladder Cancer (NMIBC)?

NMIBC represents a subset of bladder cancers confined to the inner lining of the bladder wall. It is categorized as low, intermediate, or high risk, depending on tumor size, multiplicity, and the presence of CIS. Approximately 10 percent of NMIBC patients are diagnosed with CIS, a flat but aggressive form of cancer that requires close management.

The reliance on BCG has long been the standard of care, but when patients become unresponsive, treatment options have been scarce. Radical cystectomy has remained the fallback. The approval of Inlexzo helps close a treatment gap that has persisted for decades.

How Inlexzo Works?

Inlexzo is not a traditional infusion or oral drug. It uses a drug-eluting intravesical system, placed inside the bladder during a short, office-based procedure. It does not require general anesthesia and begins releasing gemcitabine immediately, maintaining extended exposure directly to the bladder tissue. This approach is significant for two reasons:

• It keeps the chemotherapy localized, limiting systemic exposure.
• It allows for continuous therapeutic action without repeated, invasive interventions.
• For many patients, this translates into a treatment that is not only effective but also easier to tolerate and less disruptive to daily life.

Risks, Safety, and Limitations

While Inlexzo is a major advancement, it is not without risks. The FDA has issued clear precautions:

• Patients with bladder perforations or compromised bladder lining should not receive Inlexzo, as systemic exposure to gemcitabine may cause severe reactions.
• Delaying cystectomy in patients with persistent CIS could increase the risk of progression to muscle-invasive or metastatic bladder cancer, which is often lethal.
• MRI safety is limited to specific conditions, requiring close adherence to guidelines.

Reproductive risks include embryo-fetal toxicity and potential male infertility, based on animal studies. Women are advised to avoid pregnancy during treatment and for at least a week after device removal.

The most common side effects include urinary frequency, infections, bladder irritation, and blood in the urine. Serious adverse events occurred in 24 percent of patients, with 1.2 percent experiencing fatal outcomes, though these were rare.

Is This System A Patient-Centered Shift in Bladder Cancer Care?

Bladder cancer disproportionately impacts older adults—72 percent of patients in the SunRISe-1 study were over 65 years old. For this group, surgery carries heightened risks. Inlexzo’s approval gives clinicians a new tool to help manage NMIBC without immediately resorting to bladder removal.

As Dr. Daneshmand noted, this drug-delivery innovation may change the treatment landscape by filling a crucial gap in care. For patients who have exhausted BCG and face limited choices, Inlexzo offers hope for improved survival and quality of life.

Inlexzo’s approval is a win not only for patients but also for the field of urologic oncology. The drug’s placement under Johnson & Johnson’s portfolio signals strong industry investment in localized, bladder-preserving therapies.

Experts caution, however, that long-term follow-up studies will be essential to fully understand Inlexzo’s durability, risks, and potential role in combination with other therapies. For now, the FDA’s decision gives patients an urgently needed option that bridges the gap between immunotherapy failure and radical surgery.

When it comes to tackling chronic disease, the United States is lagging behind its peers. A new study published in The Lancet reveals that among 25 high-income Western countries, the US has shown the slowest progress in reducing deaths from noncommunicable diseases such as cancer, heart disease, stroke, and diabetes.

The research, led by Imperial College London, analyzed mortality data from 185 countries between 2010 and 2019. While most nations reported overall declines in the probability of dying before age 80 from chronic disease, the US not only saw smaller reductions compared with other wealthy countries but also a troubling rise in deaths among younger adults aged 20 to 45.

The data show that between 2010 and 2019, deaths from chronic disease decreased in most US age groups but increased among young adults, a rare and alarming trend for a high-income country. Researchers describe this as “a rare phenomenon in high-income Western countries,” suggesting that the problem is systemic, not just demographic.

Majid Ezzati, the study’s senior author and professor of global health at Imperial, explained that while older Americans benefited from improved treatments and detection for heart disease and cancer, younger generations faced new and worsening risks including obesity, alcohol use disorders, and neuropsychiatric conditions like dementia.

The global picture provides a stark contrast. Roughly 80 percent of countries saw reductions in chronic disease mortality during the past decade, covering more than 70 percent of the world’s population. Denmark led the high-income group with the steepest decline, followed closely by Norway and Finland. Germany performed poorly as well, showing only slightly better results than the US.

While all high-income countries experienced a slowdown in the rate of decline compared to earlier decades, the United States stood out for its stagnation in working-age adults and actual increases in younger adults. Other countries managed to balance slower declines in older age groups with sharper improvements in working-age populations, but the US did not.

Why Is the US Falling Behind in Mortality?

The study did not dive into root causes, but experts point to a combination of health system and social factors:

Healthcare access and disparities: Millions of Americans lack consistent primary care, delaying diagnosis and treatment of chronic conditions. Without a physician close to home, routine screenings often fall through the cracks.

Social determinants of health: Income inequality, food insecurity, and limited access to healthy lifestyles all disproportionately affect younger and working-age adults.

Rise in neuropsychiatric conditions: While cancer and heart disease deaths declined, increases in dementia, alcohol use disorders, and mental health-related conditions offset gains.

Obesity and lifestyle factors: Rising rates of obesity, poor diets, and sedentary behavior have made chronic diseases harder to control, particularly among younger people.

Ezzati emphasized that underinvestment in public health is a common denominator. “In both the US and Germany, there are segments of the population in which there has been less investment in public health, and these disparities in investment can lead to broad barriers to accessing care,” he said.

Is This A Global Slowdown, Not Just an American Problem?

The US may be the slowest among wealthy nations, but it is not alone in struggling. Nearly two-thirds of all countries saw slower progress in reducing chronic disease mortality during 2010–2019 compared with the previous decade.

In northern Europe, for example, Denmark and Finland reported slower improvements among older adults, but these were offset by faster progress among working-age adults. That balance prevented them from stagnating as the US did.

Globally, the slowdown raises concerns about whether countries will meet the UN Sustainable Development Goal of reducing premature mortality from noncommunicable diseases by one-third by 2030.

So what sets top performers like Denmark apart? Researchers credit strong investment in preventive health, early detection, and broad access to primary care. Comprehensive strategies for cardiovascular disease prevention, aggressive anti-smoking campaigns, and early cancer screening programs have made a measurable impact.

By contrast, the US has struggled to implement nationwide preventive programs. Even when effective interventions exist — like lifestyle counseling, preventive screenings, and access to affordable medications, barriers in insurance coverage, geography, and affordability keep many Americans from benefiting.

Perhaps the most sobering aspect of the study is that progress is slowing not just in the US but worldwide. Improvements in diagnosis and treatment that once drove sharp declines in chronic disease deaths may be reaching their limits. Unless new strategies are adopted — especially those that reach disadvantaged populations — gains could stall entirely or even reverse.

For the US, where chronic diseases already account for 6 in 10 deaths, the message is clear: without significant investment in prevention and equitable healthcare access, the gap with peer nations will only widen.

Ezzati summed up the findings with a blunt warning, “The risk of dying from chronic diseases in most countries in the world is coming down. But we were doing better before.”

The All India Institute of Medical Sciences (AIIMS) in New Delhi has created a new mental health program called "Never Alone." The program was launched on World Suicide Prevention Day to directly address the serious issue of student suicides and to improve mental health awareness.

"Never Alone" is an AI-based tool designed to help students who may be struggling with suicidal thoughts and other mental health challenges. Its main goal is to reduce the negative social stigma that often prevents people from seeking help and to make it easier for them to access professional support.

How the App Works?

The "Never Alone" app is a very secure and personalized program that students can use anytime, day or night. It works through a web app that can be easily accessed via WhatsApp. For a very low cost of just 70 paisa per student per day, institutions can subscribe to the service and offer it to their students.

Also Read: Physiotherapists Are Not Doctors, Cannot Use ‘Dr’ Title, Rules Health Authority In India

The app provides a secure mental health screening and gives students access to both online and in-person consultations with trained mental health experts. This setup makes getting help more convenient and private, which can be very important for students who might feel uncomfortable talking about their struggles in person.

Growing Crisis Among Young Adults

This program was launched to tackle a serious national problem. According to government data, in 2022, more than 1.7 lakh people died by suicide in India. What's especially concerning is that a large portion of these deaths—35%—were among young adults between the ages of 18 and 30.

Experts say a big reason for this is that many people with mental health issues don't get the help they need. This is often due to a lack of awareness and the fear of being judged by others. The "Never Alone" app aims to fill this gap by providing a confidential and accessible way for students to get support.